skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Bevacizumab (Code C2039)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Bevacizumab

Definition: A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

NCI-GLOSS Definition: A drug used to treat several types of cancer, including certain types of colorectal, lung, breast, and kidney cancers and glioblastoma. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may prevent the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.

Display Name: Bevacizumab

Label: Bevacizumab

NCI Thesaurus Code: C2039 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0796392  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Anti-VEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF rhuMAb
Avastin
Bevacizumab
BEVACIZUMAB
bevacizumab
Bevacizumab Biosimilar BEVZ92
Bevacizumab Biosimilar BI 695502
Bevacizumab Biosimilar CBT 124
Bevacizumab Biosimilar FKB238
Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer
Recombinant Humanized Anti-VEGF Monoclonal Antibody
rhuMab-VEGF

External Source Codes: 
CAS Registry Number 216974-75-3 (see NLM ChemIDplus info)
FDA UNII Code 2S9ZZM9Q9V
NSC Code 704865 (see NCI DTP info)
PDQ Closed Trial Search ID 43234
PDQ Open Trial Search ID 43234 (check for NCI PDQ open clinical trial info)
UMLS CUI C0796392

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Metastatic Colorectal Cancer, Non-small Cell Lung Cancer, glioblastoma; Metastatic Renal Cell Carcinoma
code C2039
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Bevacizumab
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: Yes  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2039

Mainbox Bottom